The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
Abstract
Objective: Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA). Methods: Patients with moderately to severely active PsA and a history of inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive 40 mg adalimumab or placebo subcutaneously every other week for 24 weeks. Study visits were at baseline, weeks 2 and 4, and every 4 weeks thereafter. The primary efficacy end points were the American College of Rheumatology 20% improvement (ACR20) response at week 12 and the change in the modified total Sharp score of structural damage at week 24. Secondary end points were measures of joint disease, disability, and quality of life in all patients, as well as the severity of skin disease in those patients with psoriasis involving at least 3% of body surface area. Results: At week 12, 58% of the adalimumab‐treated patients (87 of 151) achieved an ACR20 response, compared with 14% of the placebo‐treated patients (23 of 162) (P < 0.001). At week 24, similar ACR20 response rates were maintained and the mean change in the modified total Sharp score was −0.2 in patients receiving adalimumab and 1.0 in those receiving placebo (P < 0.001). Among the 69 adalimumab‐treated patients evaluated with the Psoriasis Area and Severity Index (PASI), 59% achieved a 75% PASI improvement response at 24 weeks, compared with 1% of the 69 placebo‐treated patients evaluated (P < 0.001). Disability and quality of life measures were also significantly improved with adalimumab treatment compared with placebo. Adalimumab was generally safe and well‐tolerated. Conclusion: Adalimumab significantly improved joint and skin manifestations, inhibited structural changes on radiographs, lessened disability due to joint damage, and improved quality of life in patients with moderately to severely active PsA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Current estimates from the National Health Interview Survey.
Ss, J. (1981) · PubMed · Cited by 1,866
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Self-citationLam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P., & Teitelbaum, S. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11176 · Cited by 1,440
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.
Fries, J. F., Spitz, P. W., & Young, D. Y. (1982) · PubMed · Cited by 1,318
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Self-citationEtanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J. T., & Tsuji, W. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20335 · Cited by 882
Self-citationAntoni, C. E., Kavanaugh, A., Kirkham, B., Tutuncu, Z., Burmester, G. R., Schneider, U., Furst, D. E., Molitor, J., Keystone, E., Gladman, D., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20967 · Cited by 640
Self-citationPsoriatic Arthritis (PSA) - An Analysis of 220 Patients
(1987) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068085 · Cited by 639
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Epidemiology of psoriatic arthritis in the population of the United States
Gelfand, J. M., Gladman, D. D., Mease, P. J., Smith, N., Margolis, D. J., Nijsten, T., Stern, R. S., Feldman, S. R., & Rolstad, T. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.03.046 · Cited by 596
Self-citationTreatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes
Ellis, C. N., & Krueger, G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450403 · Cited by 582
Kosinski, M., Zhao, S. Z., Dedhiya, S., Osterhaus, J. T., & Ware, J. E. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200007)43:7<1478::aid-anr10>3.0.co;2-m · Cited by 505
Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions
ETTEHADI, P., GREAVES, M. W., WALLACH, D., ADERKA, D., & CAMP, R. D. R. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06244.x · Cited by 481
Clegg, D. O., Reda, D. J., Mejias, E., Cannon, G. W., Weisman, M. H., Taylor, T., Budiman‐Mak, E., Blackburn, W. D., Vasey, F. B., Mahowald, M. L., et al. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391210 · Cited by 447
Sharp, J. T., Young, D. Y., Bluhm, G. B., Brook, A., Brower, A. C., Corbett, M., Decker, J. L., Genant, H. K., Gofton, J. P., Goodman, N., et al. (1985) · Arthritis & Rheumatism · doi:10.1002/art.1780281203 · Cited by 417
Self-citationKaltwasser, J. P., Nash, P., Gladman, D., Rosen, C. F., Behrens, F., Jones, P., Wollenhaupt, J., Falk, F. G., & Mease, P. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20253 · Cited by 413
Self-citationThe epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.
Shbeeb, M. I., Uramoto, K. M., Gibson, L. E., O’Fallon, W. M., & Gabriel, S. E. (2000) · PubMed · Cited by 392
Methotrexate and histologic hepatic abnormalities: A meta-analysis
Whiting-O'Keefe, Q. E., Fye, K. H., & Sack, K. D. (1991) · The American Journal of Medicine · doi:10.1016/s0002-9343(05)80060-9 · Cited by 358
Partsch, G., Steiner, G. E., Leeb, B. F., Dunky, A., Bröll, H., & Smolen, J. S. (1997) · PubMed · Cited by 297
Primer on the Rheumatic Diseases
(2008) · Springer eBooks · doi:10.1007/978-0-387-68566-3 · Cited by 253
Unemori, E. N., Hibbs, M. S., & Amento, E. P. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115480 · Cited by 193
Feletar, M., Brockbank, J. E., Schentag, C. T., Lapp, V., & Gladman, D. D. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.006775 · Cited by 97
Self-citationTNFα therapy in psoriatic arthritis and psoriasis
Mease, P. J. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.020719 · Cited by 96
Self-citationPotential of Tumor Necrosis Factor Inhibitors in Psoriasis and Psoriatic Arthritis
Krueger, G. G., & Callis, K. P. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.2.218 · Cited by 96
Interventions for treating psoriatic arthritis
Jones, G., Crotty, M., & Brooks, P. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000212 · Cited by 92
Hanauer, S. B., Lukáš, M., MacIntosh, D. G., Rutgeerts, P. J., Sandborn, W. J., & Pollack, P. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.05.010 · Cited by 65
Linking outcomes management to quality-of-life measurement.
Cella, D. F., & Webster, K. (1997) · PubMed · Cited by 47
Cited by
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Greb, J. E., Goldminz, A. M., Elder, J. T., Lebwohl, M. G., Gladman, D. D., Wu, J. J., Mehta, N. N., Finlay, A. Y., & Gottlieb, A. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.82 · Cited by 922
Self-citationvan der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21913 · Cited by 872
McInnes, I. B., Mease, P. J., Kirkham, B., Kavanaugh, A., Ritchlin, C. T., Rahman, P., van der Heijde, D., Landewé, R., Conaghan, P. G., Gottlieb, A. B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61134-5 · Cited by 858
Self-citation
Metadata
- Authors
- Mease, P. J., Gladman, D. D., Ritchlin, C. T., Ruderman, E. M., Steinfeld, S. D., Choy, E. H. S., Sharp, J. T., Ory, P. A., Perdok, R. J., & Weinberg, M. A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-09-30
- Volume
- 52
- Issue
- 10
- Pages
- 3279-3289
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2133696182
- Cited by
- 909
- References
- 37
- FWCI
- 32.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.